Active Biotech Ab

Frederik Ivars

Per Bjork

Tomas Leanderson

A method of identifying a compound for use in therapy which modulates the interaction of S1OO A9 with a ligand comprising:&#x2014;determining whether a candidate compound is capable of modulating the interaction of S1OO A9 with RAGE or the interaction of S1OO A9 with a TLR (Toll like receptor), or&#x2014;determining whether a candidate compound is capable of binding to S100A9 in a manner which disrupts binding of S1OO A9 with RAGE or the binding of S100A9 with a TLR, to thereby identify whether the compound may be used in therapy.

Growing community of inventors

Lund, Sweden

Frederik Ivars